The commonly used immunohistochemical markers CD5 and CD117 have only moderate sensitivity (33–73% and 65–85%, respectively) and imperfect specificity (72–100% and 85–100%, respectively) for the distinction of thymic carcinoma from thymoma [4,5,6,7,8]. The gene discussed is CD5; the disease is thymoma.